Global Pharmaceuticals Survey Series (Part II): Ophthalmology We present the second edition of the Credit Suisse Global Pharmaceuticals Survey November 6, 2013 Series with insights on the eye market. RESEARCH TEAM Key takeaways from our survey of 47 high prescribing optometrists and Vamil Divan, MD ophthalmologists include: (1) growth for AGN’s Restasis is expected to continue in the (212)-538-5394 medium term, with FDA decision on substitutability of generic version critical determinant to
[email protected] longer-term, (2) AGN’s Lumigan is poised to maintain branded market leadership in Jason Kantor, PhD glaucoma with low share loss expected, (3) REGN/BAY’s Eylea positive momentum will likely (415) 249-7942
[email protected] continue post upcoming entry in diabetic macular edema, and (4) there is room for pipeline drugs assuming improvements in key characteristics such as dosing profile and efficacy. Ari Jahja (212) 325-0767
[email protected] Conclusions from survey results for key players are the following: European Pharma Team (44)-207-888-0304 AGN: The results underpin our view that Lumigan is poised to maintain market leadership in
[email protected] branded prostaglandin market, despite stricter formulary management and competition from Fumiyoshi Sakai generic latanoprost. While meaningful share erosion is likely for Restasis post entry of (81) 3-4550-9737 version, medium-term growth is likely to continue. We remain cautious on pipeline drugs
[email protected] DARPin and Ozurdex in DME, which represent optionality in our model. Jeremiah Shepard, PhD (415) 249-7933 REGN/BAY: Eylea
[email protected] Key findings support our positive view on , of which growth will accelerate post approval in diabetic macular edema (DME) amid expected stable share in wet age- Ronak H.